Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2013 1
2014 1
2015 5
2016 5
2017 2
2018 2
2019 2
2020 3
2021 6
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
Vasseur L, Fenwarth L, Lambert J, de Botton S, Figeac M, Villenet C, Heiblig M, Dumas PY, Récher C, Berthon C, Lemasle E, Lebon D, Lambert J, Terré C, Celli-Lebras K, Dombret H, Preudhomme C, Cheok M, Itzykson R, Duployez N. Vasseur L, et al. Among authors: lemasle e. Blood Adv. 2023 Aug 8;7(15):4024-4034. doi: 10.1182/bloodadvances.2023010155. Blood Adv. 2023. PMID: 37205853 Free PMC article.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Marmouset V, et al. Among authors: lemasle e. Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. Clin Cancer Res. 2022. PMID: 36201165
Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study.
Pénichoux J, Lanic H, Thill C, Ménard AL, Camus V, Stamatoullas A, Lemasle E, Leprêtre S, Lenain P, Contentin N, Kraut-Tauzia J, Fruchart C, Kammoun L, Damaj G, Farge A, Delette C, Modzelewski R, Vaudaux S, Pépin LF, Tilly H, Jardin F. Pénichoux J, et al. Among authors: lemasle e. Ann Hematol. 2023 Jul;102(7):1811-1823. doi: 10.1007/s00277-023-05200-x. Epub 2023 Apr 14. Ann Hematol. 2023. PMID: 37058153 Free PMC article.
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock.
Herault A, Lévêque E, Draye-Carbonnier S, Decazes P, Zduniak A, Modzelewski R, Libraire J, Achamrah N, Ménard AL, Lenain P, Contentin N, Grall M, Leprêtre S, Lemasle E, Lanic H, Alani M, Stamatoullas-Bastard A, Tilly H, Jardin F, Tamion F, Camus V. Herault A, et al. Among authors: lemasle e. Clin Nutr ESPEN. 2023 Jun;55:373-383. doi: 10.1016/j.clnesp.2023.04.007. Epub 2023 Apr 22. Clin Nutr ESPEN. 2023. PMID: 37202070 Free article.
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
Zduniak A, Lévêque E, Perdrix A, Etancelin P, Ménard AL, Lenain P, Contentin N, Pépin LF, Leprêtre S, Lemasle E, Lanic H, Stamatoullas-Bastard A, Kammoun-Quique L, Tilly H, Bauer F, Jardin F, Camus V. Zduniak A, et al. Among authors: lemasle e. Leuk Lymphoma. 2022 Dec;63(14):3340-3350. doi: 10.1080/10428194.2022.2123222. Epub 2022 Sep 18. Leuk Lymphoma. 2022. PMID: 36120853
Prognostic relevance of lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience.
Pénichoux J, Dubois S, Krzisch D, Menard AL, Lanic H, Camus V, Lemasle E, Leprêtre S, Lenain P, Contentin N, Daliphard S, Buchonnet G, Penther D, Bastard C, Tilly H, Jardin F, Stamatoullas A. Pénichoux J, et al. Among authors: lemasle e. Leuk Lymphoma. 2021 Sep;62(9):2272-2275. doi: 10.1080/10428194.2021.1907381. Epub 2021 Apr 2. Leuk Lymphoma. 2021. PMID: 33797310 No abstract available.
Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.
Camus V, Viennot M, Lequesne J, Viailly PJ, Bohers E, Bessi L, Marcq B, Etancelin P, Dubois S, Picquenot JM, Veresezan EL, Cornic M, Burel L, Loret J, Becker S, Decazes P, Lenain P, Lepretre S, Lemasle E, Lanic H, Ménard AL, Contentin N, Tilly H, Stamatoullas A, Jardin F. Camus V, et al. Among authors: lemasle e. Haematologica. 2021 Jan 1;106(1):154-162. doi: 10.3324/haematol.2019.237719. Haematologica. 2021. PMID: 32079702 Free PMC article.
Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.
Candon S, Lemee V, Leveque E, Etancelin P, Paquin C, Carette M, Contentin N, Bobee V, Alani M, Cardinael N, Lepretre S, Camus V, Bouclet F, Boulet E, Menard AL, Lanic H, Stamatoullas A, Lemasle E, Pepin LF, Richard D, Dubois S, Tilly H, Dalleac A, Plantier JC, Etienne M, Jardin F. Candon S, et al. Among authors: lemasle e. Haematologica. 2022 Mar 1;107(3):755-758. doi: 10.3324/haematol.2021.280139. Haematologica. 2022. PMID: 34854280 Free PMC article. No abstract available.
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, Thomas X, Marceau-Renaut A, Chantepie S, Malfuson JV, Lemasle E, Cheok M, Celli-Lebras K, Guerin E, Terré C, Lambert J, Pautas C, Dombret H, Castaigne S, Preudhomme C, Boissel N. Fournier E, et al. Among authors: lemasle e. Blood. 2020 Feb 20;135(8):542-546. doi: 10.1182/blood.2019003471. Blood. 2020. PMID: 31880804 Free article. Clinical Trial.
35 results